In breast cancer, the dependency on glycolysis for CD44+ CSCs has been demonstrated by the enrichment of essential enzymes of glycolysis for maintaining cancer stem-like properties under hypoxic conditions (209, 210). The gene discussed is CD44; the disease is cancer.